0001140361-24-032245.txt : 20240702
0001140361-24-032245.hdr.sgml : 20240702
20240702210019
ACCESSION NUMBER: 0001140361-24-032245
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240630
FILED AS OF DATE: 20240702
DATE AS OF CHANGE: 20240702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Grossman Adam S
CENTRAL INDEX KEY: 0001542517
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36728
FILM NUMBER: 241098029
MAIL ADDRESS:
STREET 1: 65 COMMERCE WAY
CITY: HACKENSACK
STATE: NJ
ZIP: 07601
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC.
CENTRAL INDEX KEY: 0001368514
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 562590442
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O ADMA BIOLOGICS, INC.
STREET 2: 465 STATE ROUTE 17
CITY: RAMSEY
STATE: NJ
ZIP: 07446
BUSINESS PHONE: (201) 478-5552
MAIL ADDRESS:
STREET 1: C/O ADMA BIOLOGICS, INC.
STREET 2: 465 STATE ROUTE 17
CITY: RAMSEY
STATE: NJ
ZIP: 07446
FORMER COMPANY:
FORMER CONFORMED NAME: R&R ACQUISITION VI, INC
DATE OF NAME CHANGE: 20060707
4
1
form4.xml
FORM 4
X0508
4
2024-06-30
0001368514
ADMA BIOLOGICS, INC.
ADMA
0001542517
Grossman Adam S
C/O ADMA BIOLOGICS, INC.
465 STATE ROUTE 17
RAMSEY
NJ
07446
true
true
President,CEO, and Interim CFO
false
Common Stock
2024-06-30
4
F
0
21752
11.18
D
2059726
D
Common Stock
1143426
I
See Footnote
Common Stock
580957
I
See Footnote
Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units (RSUs). This is not an open market sale of securities.
Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
(continued from footnote 2) (iv) 113,438 unvested time-based RSUs granted on September 29, 2021, subject to time-based vesting conditions which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;
(continued from footnote 3) and (vi) 762,500 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.
/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact
2024-07-02